Zimmer Biomet Shoulder Arthroplasty PMCF Study

NCT ID: NCT06920459

Last Updated: 2025-12-08

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-04-29
• Study Completion Date: 2036-12-31

Brief Summary

This is a multicenter, prospective, non-controlled post market surveillance study. The objectives of this study are to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems in primary anatomic shoulder arthroplasty and its instrumentation. Safety of the systems will be assessed by monitoring the frequency and incidence of adverse events. The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, qualify of life, and radiographic parameters of all enrolled study subjects.

Detailed Description

The primary endpoint for this study will be performance assessed by improvement in the American Shoulder and Elbow Surgeons (ASES) shoulder score from baseline to 2 years (as evaluated using the overall cohort mean showing at least the minimal clinically important difference (MCID) of 6.4 points).

The secondary endpoint is represented by the safety of the system, which will be assessed by monitoring the frequency and incidence of adverse events. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.

Conditions

Shoulder Fractures; Shoulder Arthritis Osteoarthritis; Shoulder Injury; Shoulder Pain; Degenerative Joint Disease; Arthritis Shoulder

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Zimmer Biomet Total Shoulder Arthroplasty System

Patients who are having primary total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System

Alliance™ Glenoid

Intervention Type: DEVICE

Total Shoulder Arthroplasty using the Alliance™ Glenoid implant

Interventions

Alliance™ Glenoid

Total Shoulder Arthroplasty using the Alliance™ Glenoid implant

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient must be 20 years of age or older.
• Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
• Patient is a candidate for shoulder arthroplasty due to one or more of the following:

Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.

Rheumatoid arthritis. Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.

Difficult clinical management problems, where other method of treatment may not be suitable or may be inadequate.

• Patient must be able and willing to complete the protocol required follow-up.
• Patient must be able and willing to sign the IRB/EC approved informed consent.

Exclusion Criteria

• Patient is unwilling or unable to give consent or to comply with the follow-up program.
• Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
• Patient is known to be pregnant or breastfeeding.
• Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non- compliant).
• Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
• Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
• Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
• Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
• Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
• Patient has a metabolic disorder that may impair bone formation.
• Patient has osteomalacia.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zimmer Biomet

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Emilie Rohmer

Role: STUDY_DIRECTOR

Zimmer Biomet

Locations

ARCUS Kliniken Pforzheim

Pforzheim, , Germany

Site Status: ACTIVE_NOT_RECRUITING

Meander Medisch Centrum

Amersfoort, TZ, Netherlands

Site Status: RECRUITING

Countries

Germany; Netherlands

Central Contacts

Carina Hafner

Role: CONTACT

carina.hafner@zimmerbiomet.com

+41 79 707 30 93

Lisa To

Role: CONTACT

Lisa.To@zimmerbiomet.com

Facility Contacts

Dr. T.D. Berendes

Role: primary

poli_orthopedie@meandermc.nl

+31 33 850 4798

Other Identifiers

CMU2019-35E-EU

Identifier Type: -

Identifier Source: org_study_id